BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

TxCell 

Les Cardoulines HT1, Allée de la Nertière,

Sophia Antipolis   Valbonne   06560   France
Phone: 33-0-497-218-300 Fax: 33-0-493-641-580


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
TxCell And Trizell Amend Collaboration Agreement To Accelerate Ovasave Development 4/23/2015 8:50:09 AM
TxCell Strengthens Its Board Of Directors By Appointing Dr. David Solomon To Board And As Chair Of Sub-Committee 4/16/2015 10:04:13 AM
TxCell 2014 Results: Strengthening Of Cash Position And Development Of Astria Product Platform 4/1/2015 9:12:47 AM
Key TxCell Patent To Be Granted In The United States For Its Lead Product Ovasave 3/18/2015 10:31:38 AM
TxCell To Present At ROTH Capital Partners Investor Conference In U.S. 2/26/2015 10:55:24 AM
TxCell Reports Revenues For 2014 And Updates On Upcoming Milestones 2/4/2015 9:42:44 AM
TxCell Announces Its Financial Calendar For 2015 1/30/2015 9:20:17 AM
TxCell Receives EUR 1 Million Milestone Payment Regarding Ovasave® Collaboration Agreement From Trizell 1/29/2015 8:58:10 AM
TxCell Receives EUR 1.7 Million From Bpifrance For Ovasave® Clinical Development In Refractory Crohn’s Disease 1/27/2015 1:31:06 PM
TxCell To Present Its Experience With Cell Therapy At The Cell & Gene Therapy Forum 2015, Washington 1/22/2015 9:51:05 AM
1234